Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
Figure 1
Effect of lenalidomide on the proliferation of B cells. (a) PBMCs obtained from healthy donors () and CLL patients () were labeled with CFSE and cultured with 1 μM lenalidomide or DMSO for 14 days. CFSE fluorescence in B cells (gated as CD5+/CD19+) was analyzed by flow cytometry. The histograms show a representative CLL patient and a healthy donor. (b) The figure shows the compilation of the results obtained from healthy donors and CLL patients. Results are expressed as the fold induction of the percentage of proliferating B cells in lenalidomide-treated cells relative to the vehicle-treated control (, Mann-Whitney U test).
